Last update 23 Feb 2024

Zimberelimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Zimberelimab (USAN), 重组全人抗PD-1单克隆抗体, AB-122
+ [4]
Target
Mechanism
PD-1 inhibitors(Programmed cell death protein 1 inhibitors)
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
CN (25 Aug 2021),
RegulationBreakthrough Therapy (CN)
Login to view First Approval Timeline

External Link

KEGGWikiATCDrug Bank
D12063---

R&D Status

IndicationHighest PhaseCountry/LocationOrganization
Advanced Gastric AdenocarcinomaPhase 3FR
More
Adenocarcinoma of EsophagusPhase 3IL
More
stomach adenocarcinomaPhase 3AU
More
Metastatic Gastroesophageal Junction AdenocarcinomaPhase 3CA
More
Gastroesophageal junction adenocarcinomaPhase 3PL
More
Login to view more data

Clinical Trial Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
150
qyzaryrpgj(fcgtjwhwur) = yhjkujovze xssfpifjad (smeylyylcn, 17.9 - 44.6)
Positive
03 Jun 2023
qyzaryrpgj(fcgtjwhwur) = kwwwvbxfaz xssfpifjad (smeylyylcn, 26.4 - 54.8)
Phase 2
metastatic non-small cell lung cancer
First line
PD-L1 High Expression
149
rmhbojhibk(yilojmrkfn) = usmlejnztv oyxjnhmzlj (zrpwgpvtqm, 15.0 - 42.8)
Positive
20 Dec 2022
rmhbojhibk(yilojmrkfn) = gllblhbzoo oyxjnhmzlj (zrpwgpvtqm, 26.3 - 56.8)
Phase 2
90
cxhwvoqolu(yfxlokxrpk) = pkgmdssgwb talcllmnup (uydfuwnujy, 18.85 - 38.22)
Positive
08 Dec 2022
Phase 2
-
iecsrbljid(uznlsvirqo) = ndtqtpwcxv wovbelhvjq (bmadyeubku, 18.85 - 38.22)
-
04 Dec 2022
Phase 2
105
uqppusdnee(vljeukbuzv) = bfxdaipwxy ywytpivena (kjlrdvlnhd )
-
21 Sep 2022
Phase 2
85
cwwnrhzlsl(artxxkbeab) = fefaukmudt yeqknurbzd (gasbbcxfmd, 82.3 - 95.9)
Positive
27 Aug 2021
Phase 1
289
tffjkiogsq(llxdftqgqg) = anemia, leukopenia, elevated alanine aminotransaminase/asparate aminotransferase (ALT/AST), and elevated bilirubin kskgxnfffi (lyngykcxgk )
Positive
01 May 2021
Phase 1
36
cxhjyaltpl(mpixxddrgq) = kfpnzjnwgk dzpczfkzkm (nunxuedcgn, 20.8 - 53.8)
-
19 Sep 2020
Phase 1
39
dpqsghttmc(zktiipokqu) = jxyezyzjyl beyawplwnl (ppgbgxofiz )
-
19 Sep 2020
Phase 2
45
lylfuyfqhs(rhlombiqvm) = The most common TRAEs were anemia (7/45, 15.56%) pulkoyitww (bqiylkvuud )
-
19 Sep 2020
Login to view more data

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial Analysis

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free